Efficacy and safety profile of aliskiren: Practical implications for clinicians

Current Drug Safety

Volumn 9, Issue 2, 2014, Pages 106-117

  Angeli, Fabio ^a   Reboldi, Gianpaolo ^b   Poltronieri, Cristina ^a   Angeli, Enrica ^a   De Filippo, Valentina ^c   Crocetti, Alessandra ^c   Bartolini, Claudia ^c   D'Ambrosio, Cinzia ^c   Verdecchia, Paolo ^c  

^a Teaching Hospital SM della Misericordia   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

^c Hospital of Assisi   (Italy)

Author keywords

Aliskiren; Blood pressure reduction; Combination therapy; Hypertension; Prognosis; Renin angiotensin system; Treatment

Indexed keywords

ALDOSTERONE; ALISKIREN; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; AMIDE; ANTIHYPERTENSIVE AGENT; FUMARIC ACID DERIVATIVE; RENIN;

ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; COUGHING; DIABETES MELLITUS; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GLUCOSE METABOLISM; HEADACHE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; KIDNEY DISEASE; MONOTHERAPY; NONHUMAN; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINOPHARYNGITIS; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD PRESSURE; DRUG COMBINATION; DRUG EFFECTS; HYPERTROPHY, LEFT VENTRICULAR;

AMIDES; ANIMALS; ANTIHYPERTENSIVE AGENTS; ATHEROSCLEROSIS; BLOOD PRESSURE; DRUG THERAPY, COMBINATION; FUMARATES; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; RENIN;

EID: 84904721169     PISSN: 15748863     EISSN: None     Source Type: Journal    
DOI: 10.2174/1389450115666140211113040     Document Type: Article

References (103)

1. Grothusen C, Bley S, Selle T, et al. Combined effects of hmg-coareductase inhibition and renin-angiotensin system blockade on experimental atherosclerosis. Atherosclerosis 2005; 182: 57-69.
2. Grote K, Drexler H, Schieffer B. Renin-angiotensin system and atherosclerosis. Nephrol Dial Transplant 2004; 19: 770-773.
3. Pagliaro P, Penna C. Rethinking the renin-angiotensin system and its role in cardiovascular regulation. Cardiovasc Drugs Ther 2005; 19: 77-87.
4. Dzau V. The cardiovascular continuum and renin-angiotensinaldosterone system blockade. J Hypertens 2005; 23: S9-17.
5. Dzau VJ, Bernstein K, Celermajer D, et al. The relevance of tissue angiotensin-converting enzyme: Manifestations in mechanistic and endpoint data. Am J Cardiol 2001; 88: 1-20L.
6. Dzau VJ. Theodore cooper lecture: Tissue angiotensin and pathobiology of vascular disease: A unifying hypothesis. Hypertension 2001; 37: 1047-1052.
7. Nguyen Dinh Cat A, Touyz RM. A new look at the reninangiotensin system--focusing on the vascular system. Peptides 2011; 32: 2141-2150.
8. Angeli F, Gentile G, Reboldi G, Verdecchia P. Angiotensinconverting enzyme inhibitors, angiotensin receptor blockers and protection from stroke. Expert Rev Cardiovasc Ther 2008; 6: 1171-1174.
9. Angeli F, Reboldi G, Verdecchia P. Modern treatment of patients at risk: Still a hope for ace inhibitors? Expert Opin Pharmacother 2011; 12: 839-843.
10. Angeli F, Verdecchia P, Reboldi GP, et al. Meta-analysis of effectiveness or lack thereof of angiotensin-converting enzyme inhibitors for prevention of heart failure in patients with systemic hypertension. Am J Cardiol 2004; 93: 240-243.
11. Reboldi G, Angeli F, Cavallini C, Gentile G, Mancia G, Verdecchia P. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: A meta-analysis. J Hypertens 2008; 26: 1282-1289.
12. Verdecchia P, Angeli F, Cavallini C, et al. Blood pressure reduction and renin-angiotensin system inhibition for prevention of congestive heart failure: A meta-analysis. Eur Heart J 2009; 30: 679-688.
13. Verdecchia P, Angeli F, Mazzotta G, Ambrosio G, Reboldi G. Angiotensin converting enzyme inhibitors and angiotensin receptor blockers in the treatment of hypertension: Should they be used together? Curr Vasc Pharmacol 2010; 8: 742-746.
14. Verdecchia P, Angeli F, Mazzotta G, Gentile G, Reboldi G. The renin angiotensin system in the development of cardiovascular disease: Role of aliskiren in risk reduction. Vasc Health Risk Manag 2008; 4: 971-981.
15. Verdecchia P, Angeli F, Repaci S, Mazzotta G, Gentile G, Reboldi G. Comparative assessment of angiotensin receptor blockers in different clinical settings. Vasc Health Risk Manag 2009; 5: 939-948.
16. Verdecchia P, Cavallini C, Angeli F, et al. [Antihypertensive therapy and cardiovascular prevention. The role of angiotensin ii receptor blockers]. G Ital Cardiol (Rome) 2007; 8: 491-497.
17. Verdecchia P, Reboldi G, Angeli F, et al. Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension 2005; 46: 386-392.
18. Reboldi G, Gentile G, Angeli F, Verdecchia P. Choice of ace inhibitor combinations in hypertensive patients with type 2 diabetes: Update after recent clinical trials. Vasc Health Risk Manag 2009; 5: 411-427.
19. Reboldi G, Gentile G, Angeli F, Verdecchia P. Exploring the optimal combination therapy in hypertensive patients with diabetes mellitus. Expert Rev Cardiovasc Ther 2009; 7: 1349-1361.
20. Reboldi G, Gentile G, Angeli F, Verdecchia P. Optimal therapy in hypertensive subjects with diabetes mellitus. Curr Atherosclerosis Reports 2011; 13: 176-185.
21. Verdecchia P, Angeli F. Assessment of the optimal daily dose of valsartan in patients with hypertension, heart failure, or both. Clin Ther 2004; 26: 460-472.
22. Verdecchia P, Angeli F. Antihypertensive drugs and coronary artery disease: Evidence from controlled trials. High blood pressure & cardiovascular prevention: the official J Italian Soc Hypertens 2005; 12: 119-124.
23. Verdecchia P, Angeli F, Cavallini C, et al. The optimal blood pressure target for patients with coronary artery disease. Curr Cardiol Rep 2010; 12: 302-306.
24. Verdecchia P, Angeli F, Gattobigio R, Reboldi GP. Do angiotensin ii receptor blockers increase the risk of myocardial infarction? Eur Heart J 2005; 26: 2381-2386.
25. Verdecchia P, Angeli F, Gentile G, Mazzotta G, Reboldi G. Telmisartan for the reduction of cardiovascular morbidity and mortality. Expert Rev Clin Pharmacol 2011; 4: 151-161.
26. Verdecchia P, Angeli F, Mazzotta G, Ambrosio G, Reboldi G. Angiotensin receptor blockers in hypertension. New insights from japan. Hypertens Res 2010; 33: 394-397.
27. Verdecchia P, Gentile G, Angeli F, Reboldi G. Beyond blood pressure: Evidence for cardiovascular, cerebrovascular, and renal protective effects of renin-angiotensin system blockers. Ther Adv Cardiovasc Dis 2012; 6: 81-91.
28. Fisher ND, Meagher EA. Renin inhibitors. J Clin Hypertens (Greenwich) 2011; 13: 662-666.
29. Wood JM, Schnell CR, Cumin F, Menard J, Webb RL. Aliskiren, a novel, orally effective renin inhibitor, lowers blood pressure in marmosets and spontaneously hypertensive rats. J Hypertens 2005; 23: 417-426.
30. Azizi M, Frank M, Steichen O, Blanchard A. [Advantages and limitations of renin inhibition with aliskiren]. Ann Pharm Fr 2011; 69: 142-150.
31. Brown MJ. Aliskiren. Circulation 2008; 118: 773-784.
32. Wood JM, Maibaum J, Rahuel J, et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun 2003; 308: 698-705.
33. Musini VM, Fortin PM, Bassett K, Wright JM. Blood pressure lowering efficacy of renin inhibitors for primary hypertension. Cochrane Database Syst Rev 2008: CD007066.
34. Verdecchia P, Angeli F, Mazzotta G, et al. Aliskiren versus ramipril in hypertension. Ther Adv Cardiovasc Dis 2010; 4: 193-200.
35. Zhu JR, Sun NL, Yang K, et al. Efficacy and safety of aliskiren, a direct renin inhibitor, compared with ramipril in asian patients with mild to moderate hypertension. Hypertens Res 2012; 35: 28-33.
36. Angeli F, Reboldi G, Mazzotta G, Poltronieri C, Verdecchia P. Safety and efficacy of aliskiren in the treatment of hypertension: A systematic overview. Exp Opin Drug Saf 2012; 11: 659-670.
37. Angeli F, Reboldi G, Mazzotta G, et al. Safety and efficacy of aliskiren in the treatment of hypertension and associated clinical conditions. Curr Drug Saf 2012; 7: 76-85.
38. Angeli F, Reboldi G, Verdecchia P. Finding a place for aliskiren in the wide spectrum of blood pressure lowering agents. Hypertens Res 2012; 35: 17-19.
39. Reboldi G, Gentile G, Angeli F, Verdecchia P. Pharmacokinetic, pharmacodynamic and clinical evaluation of aliskiren for hypertension treatment. Exp Opin Drug Metab Toxicol 2011; 7: 115-128.
40. Haynes RB, Wilczynski N, McKibbon KA, Walker CJ, Sinclair JC. Developing optimal search strategies for detecting clinically sound studies in medline. J Am Med Inform Assoc 1994; 1: 447-458.
41. Musini VM, Fortin PM, Bassett K, Wright JM. Blood pressure lowering efficacy of renin inhibitors for primary hypertension: A cochrane systematic review. J Hum Hypertens 2009; 23: 495-502.
42. Kushiro T, Itakura H, Abo Y, Gotou H, Terao S, Keefe DL. Aliskiren, a novel oral renin inhibitor, provides dose-dependent efficacy and placebo-like tolerability in japanese patients with hypertension. Hypertens Res 2006; 29: 997-1005.
43. Jordan J, Engeli S, Boye SW, Le Breton S, Keefe DL. Direct renin inhibition with aliskiren in obese patients with arterial hypertension. Hypertension 2007; 49: 1047-1055.
44. Oh BH, Mitchell J, Herron JR, Chung J, Khan M, Keefe DL. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol 2007; 49: 1157-1163.
45. Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: A randomized, double-blind trial. Lancet 2007; 370: 221-229.
46. Pool JL, Schmieder RE, Azizi M, et al. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens 2007; 20: 11-20.
47. Villamil A, Chrysant SG, Calhoun D, et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens 2007; 25: 217-226.
48. Dahlof B, Anderson D, Arora V. Aliskiren, a direct renin inhibitor, provides antihypertensive efficacy and excellent tolerability independent of age or gender in patients with hypertension. J Clin Hypertens 2007; 9(Suppl A): A157.
49. Schmieder RE, Philipp T, Guerediaga J, Gorostidi M, Bush C, Keefe DL. Aliskiren-based therapy lowers blood pressure more effectively than hydrochlorothiazide-based therapy in obese patients with hypertension: Sub-analysis of a 52-week, randomized, double-blind trial. J Hypertens 2009; 27: 1493-1501.
50. Anderson VR, Perry CM, Robinson DM. Ramipril: A review of its use in preventing cardiovascular outcomes in high-risk patients. Am J Cardiovasc Drugs 2006; 6: 417-432.
51. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigators. N Engl J Med 2000; 342: 145-153.
52. Uresin Y, Taylor AA, Kilo C, et al. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone Syst 2007; 8: 190-198.
53. Drummond W, Munger MA, Rafique EM, Maboudian M, Khan M, Keefe DL. Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy. J Clin Hypertens (Greenwich) 2007; 9: 742-750.
54. Nickenig G, Simanenkov V, Lembo G, et al. Efficacy of aliskiren/hydrochlorothiazide single-pill combinations in aliskiren non-responders. Blood Press Suppl 2008; 2: 31-40.
55. White WB, Bresalier R, Kaplan AP, et al. Safety and tolerability of the direct renin inhibitor aliskiren in combination with angiotensin receptor blockers and thiazide diuretics: A pooled analysis of clinical experience of 12, 942 patients. J Clin Hypertens (Greenwich) 2011; 13: 506-516.
56. Dietz R, Dechend R, Yu CM, et al. Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension. J Renin Angiotensin Aldosterone Syst 2008; 9: 163-175.
57. Brown MJ, McInnes GT, Papst CC, Zhang J, MacDonald TM. Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (accelerate): A randomized, parallel-group trial. Lancet 2011; 377: 312-320.
58. Liu Y, Chen K, Kou X, Han Y, Zhou L, Zeng C. Aliskiren and amlodipine in the management of essential hypertension: Metaanalysis of randomized controlled trials. PLoS One 2013; 8: e70111.
59. Verma S, Gupta MK. Aliskiren improves nitric oxide bioavailability and limits atherosclerosis. Hypertension 2008; 52: 467-469.
60. Lu H, Rateri DL, Feldman DL, et al. Renin inhibition reduces hypercholesterolemia-induced atherosclerosis in mice. J Clin Invest 2008; 118: 984-993.
61. Nussberger J, Aubert JF, Bouzourene K, Pellegrin M, Hayoz D, Mazzolai L. Renin inhibition by aliskiren prevents atherosclerosis progression: Comparison with irbesartan, atenolol, and amlodipine. Hypertension 2008; 51: 1306-1311.
62. Mihai G, Varghese J, Kampfrath T, et al. Aliskiren effect on plaque progression in established atherosclerosis using high resolution 3D MRI (ALPINE): a double-blind placebo-controlled trial. J Am Heart Assoc 2013; 2: e004879.
63. Nicholls SJ, Bakris GL, Kastelein JJ, et al. Effect of aliskiren on progression of coronary disease in patients with prehypertension: The aquarius randomized clinical trial. JAMA 2013; 310: 1135-1144.
64. Verdecchia P, Angeli F, Achilli P, et al. Echocardiographic left ventricular hypertrophy in hypertension: Marker for future events or mediator of events? Curr Opin Cardiol 2007; 22: 329-334.
65. Angeli F, Reboldi G, Verdecchia P. Echocardiographic left ventricular hypertrophy: Implications for clinicians. J Hypertens 2012; 30: 2279-2284.
66. Angeli F, Reboldi G, Verdecchia P. Microcirculation and leftventricular hypertrophy. J Hypertens 2012; 30: 477-481.
67. Verdecchia P, Angeli F. Reversal of left ventricular hypertrophy: What have recent trials taught us? Am J Cardiovasc Drugs 2004; 4: 369-378.
68. Verdecchia P, Angeli F, Borgioni C, et al. Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: A meta-analysis. Am J Hypertens 2003; 16: 895-899.
69. Verdecchia P, Angeli F, Gattobigio R, Sardone M, Pede S, Reboldi GP. Regression of left ventricular hypertrophy and prevention of stroke in hypertensive subjects. Am J Hypertens 2006; 19: 493-499.
70. Verdecchia P, Angeli F, Pittavini L, Gattobigio R, Benemio G, Porcellati C. Regression of left ventricular hypertrophy and cardiovascular risk changes in hypertensive patients. Ital Heart J: Official J Ital Federation Cardiol 2004; 5: 505-510.
71. Pilz B, Shagdarsuren E, Wellner M, et al. Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in doubletransgenic rats. Hypertension 2005; 46: 569-576.
72. Solomon SD, Appelbaum E, Manning WJ, et al. Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 2009; 119: 530-537.
73. Cleland JG, Coletta AP, Buga L, Ahmed D, Clark AL. Clinical trials update from the american college of cardiology meeting 2010: Dose, aspire, connect, stich, stop-af, cabana, race ii, everest ii, accord, and navigator. Eur J Heart Fail 2010; 12: 623-629.
74. Azizi M, Menard J. Combined blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin ii type 1 receptor antagonists. Circulation 2004; 109: 2492-2499.
75. Mooser V, Nussberger J, Juillerat L, et al. Reactive hyperreninemia is a major determinant of plasma angiotensin ii during ace inhibition. J Cardiovasc Pharmacol 1990; 15: 276-282.
76. Hollenberg NK, Fisher ND, Price DA. Pathways for angiotensin ii generation in intact human tissue: Evidence from comparative pharmacological interruption of the renin system. Hypertension 1998; 32: 387-392.
77. Wolny A, Clozel JP, Rein J, et al. Functional and biochemical analysis of angiotensin ii-forming pathways in the human heart. Circ Res 1997; 80: 219-227.
78. Bomback AS, Kshirsagar AV, Klemmer PJ. Renal aspirin: Will all patients with chronic kidney disease one day take spironolactone? Nat Clin Pract Nephrol 2009; 5: 74-75.
79. Kelly DJ, Zhang Y, Moe G, Naik G, Gilbert RE. Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats. Diabetologia 2007; 50: 2398-2404.
80. Gradman AH, Schmieder RE, Lins RL, Nussberger J, Chiang Y, Bedigian MP. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebolike tolerability in hypertensive patients. Circulation 2005; 111: 1012-1018.
81. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008; 358: 2433-2446.
82. Parving HH, Brenner BM, McMurray JJ, et al. Aliskiren trial in type 2 diabetes using cardio-renal endpoints (altitude): Rationale and study design. Nephrol Dial Transplant 2009; 24: 1663-1671.
83. Parving HH, Brenner BM, McMurray JJ, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012; 367: 2204-2213.
84. Gandhi S, Srinivasan BP, Akarte AS. Effective blockade of raas by combination of aliskiren and olmesartan improves glucose homeostasis, glomerular filtration rate along with renal variables in streptozotocin induced diabetic rats. Eur J Pharm Sci 2012; 46: 32-42.
85. Marchionne EM, Diamond-Stanic MK, Prasonnarong M, Henriksen EJ. Chronic renin inhibition with aliskiren improves glucose tolerance, insulin sensitivity, and skeletal muscle glucose transport activity in obese zucker rats. Am J Physiol Regul Integr Comp Physiol 2012; 302: R137-142.
86. Krone W, Hanefeld M, Meyer HF, et al. Comparative efficacy and safety of aliskiren and irbesartan in patients with hypertension and metabolic syndrome. J Hum Hypertens 2011; 25: 186-195.
87. Townsend RR, Forker AD, Bhosekar V, Yadao A, Keefe DL. Comparison of aliskiren/hydrochlorothiazide combination therapy and amlodipine monotherapy in patients with stage 2 systolic hypertension and type 2 diabetes mellitus. J Clin Hypertens (Greenwich) 2011; 13: 889-897.
88. McMurray JJ, Pitt B, Latini R, et al. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail 2008; 1: 17-24.
89. Mancia G, Fagard R, Narkiewicz K, et al. 2013 esh/esc guidelines for the management of arterial hypertension: The task force for the management of arterial hypertension of the european society of hypertension (esh) and of the european society of cardiology (esc). J Hypertens 2013; 31: 1281-1357.
90. Altitude halted: Adverse events when aliskiren added to ace, arb therapy. [updated 2011 december 20]. Available from: Http://www. Theheart. Org/article/1331173. Do.
91. Gheorghiade M, Bohm M, Greene SJ, et al. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: The astronaut randomized trial. JAMA 2013; 309: 1125-1135.
92. Weir MR, Bush C, Anderson DR, Zhang J, Keefe D, Satlin A. Antihypertensive efficacy, safety, and tolerability of the oral direct renin inhibitor aliskiren in patients with hypertension: A pooled analysis. J Am Soc Hypertens 2007; 1: 264-277.
93. FDA. Food and drug administration. Drug product label. Tekturna, nda no. 021985. Available from: http://www. Accessdata. F da. Gov/drugsatfda_docs/label/2011/021985s019lbl. Pdf. 2010.
94. Dieterle W, Corynen S, Vaidyanathan S, Mann J. Pharmacokinetic interactions of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine. Int J Clin Pharmacol Ther 2005; 43: 527-535.
95. Ayalasomayajula S, Tchaloyan S, Yeh CM, et al. A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with allopurinol, celecoxib and cimetidine in healthy subjects. Curr Med Res Opin 2008; 24: 717-726.
96. Vaidyanathan S, Camenisch G, Schuetz H, et al. Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: The role of p-glycoprotein in the disposition of aliskiren. J Clin Pharmacol 2008; 48: 1323-1338.
97. Aliskiren pregnancy and breastfeeding warnings. [updated 2012 january 20]. Available from: Http://www. Drugs. Com/pregnancy/aliskiren. Html.
98. Duprez DA, Munger MA, Botha J, Keefe DL, Charney AN. Aliskiren for geriatric lowering of systolic hypertension: A randomized controlled trial. J Hum Hypertens 2010; 24: 600-608.
99. Basile J, Babazadeh S, Lillestol M, Botha J, Yurkovic C, Weitzman R. Comparison of aliskiren/hydrochlorothiazide combination therapy with hydrochlorothiazide monotherapy in older patients with stage 2 systolic hypertension: Results of the action study. J Clin Hypertens (Greenwich) 2011; 13: 162-169.
100. Harel Z, Gilbert C, Wald R, Bell C, Perl J, Juurlink D, Beyene J, Shah PS. The effect of combination treatment with aliskiren and blockers of the renin-angiotensin system on hyperkalaemia and acute kidney injury: Systematic review and meta-analysis. BMJ 2012; 344: e42.
101. Verdecchia P, Angeli F. [the seventh report of the joint national committee on the prevention, detection, evaluation and treatment of high blood pressure: The weapons are ready]. Revista espanola de cardiologia 2003; 56: 843-847.
102. Verdecchia P, Angeli F. Natural history of hypertension subtypes. Circulation 2005; 111: 1094-1096.
103. Palatini P, Jung W, Shlyakhto E, Botha J, Bush C, Keefe DL. Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: Results of a randomized, double-blind study. J Hum Hypertens 2010; 24: 93-103.